Search

Displaying results 3631 - 3640 of 10000 in total
  1. Drug

    Detomidine

    go.drugbank.com/drugs/DB11556
    InvestigationalVet approved

    This drug is prescribed by veterinarians and is marketed as _Dormosedan_. Currently, it is only approved by the FDA for use in horses but has been studied for use in other large animals.

  2. Drug

    Epinastine

    go.drugbank.com/drugs/DB00751
    Approved

    It has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding

  3. Drug

    Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media

    go.drugbank.com/drugs/DB15728
    Experimental

    Umbilical-cord derived MSCs are currently being tested for numerous clinical applications due to their immunosuppressive and anti-inflammatory properties. In comparison to bone-marrow derived MSCs, these cells are more resilient, easier ...

  4. Drug

    Fosamprenavir

    go.drugbank.com/drugs/DB01319
    ApprovedInvestigational

    Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.

  5. Drug

    Lonapegsomatropin

    go.drugbank.com/drugs/DB16220
    ApprovedInvestigational

    [L36380] It was later approved by the European Commission on 13 January 2022.[L39900]

  6. Drug

    Gavestinel

    go.drugbank.com/drugs/DB06741
    Experimental

    Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM).

  7. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. … TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B

  8. Drug

    Collagenase clostridium histolyticum

    go.drugbank.com/drugs/DB00048
    ApprovedInvestigational

    Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. … [L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women.

  9. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks

  10. Drug

    Sodium iodide

    go.drugbank.com/drugs/DB11119
    ApprovedInvestigational

    Sodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition [L2065] but is more commonly used in veterinary medicine.